NASDAQ:ABOS

Acumen Pharmaceuticals (ABOS) Stock Price, News & Analysis

Acumen Pharmaceuticals logo
$0.20 -0.03 (-14.82%)
As of 03:24 PM Eastern
This is a fair market value price provided by Massive. Learn more.

About Acumen Pharmaceuticals Stock (NASDAQ:ABOS)

Advanced

Key Stats

Today's Range
$0.20
▼
$0.22
50-Day Range
$0.21
▼
$2.92
52-Week Range
$0.19
▼
$3.60
Volume
2.67 million shs
Average Volume
1.19 million shs
Market Capitalization
$14.18 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$1.00
Consensus Rating
Reduce

Company Overview

Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company developing treatments for Alzheimer’s disease. Its research focuses on soluble amyloid beta oligomers, forms of the protein that the company believes contribute to the disease.

The company’s lead investigational product, sabirnetug (ACU193), is a monoclonal antibody designed to selectively target amyloid beta oligomers. Acumen has evaluated the treatment in clinical studies of people with early Alzheimer’s disease; it is investigational and has not been approved for commercial use.

AI Generated. May Contain Errors.

Acumen Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
62nd Percentile Overall Score

ABOS MarketRank™: 
3.10861173965 of 5 stars

Acumen Pharmaceuticals scored higher than 62% of companies evaluated by MarketBeat, and ranked 341st out of 859 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Acumen Pharmaceuticals has received a consensus rating of Reduce. The company's average rating score is 1.71, and is based on no strong buy ratings, 1 buy rating, 3 hold ratings, and 3 sell ratings.

  • Upside Potential

    Acumen Pharmaceuticals has a consensus price target of $1.00, representing about 410.2% upside from its current price of $0.20.

  • Amount of Analyst Coverage

    Acumen Pharmaceuticals has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Acumen Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Acumen Pharmaceuticals are expected to grow in the coming year, from ($1.50) to ($1.22) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Acumen Pharmaceuticals is -0.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Acumen Pharmaceuticals is -0.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Acumen Pharmaceuticals has a P/B Ratio of 0.41. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    7.02% of the float of Acumen Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Acumen Pharmaceuticals has a short interest ratio ("days to cover") of 0.66, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Acumen Pharmaceuticals has recently increased by 47.42%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Acumen Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Acumen Pharmaceuticals does not have a long track record of dividend growth.

  • News Sentiment

    Acumen Pharmaceuticals has a news sentiment score of 0.41. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.51 average news sentiment score of Healthcare companies.
  • Search Interest

    6 people have searched for ABOS on MarketBeat in the last 30 days.
  • MarketBeat Follows

    3 people have added Acumen Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Acumen Pharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    10.20% of the stock of Acumen Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    71.01% of the stock of Acumen Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Acumen Pharmaceuticals' insider trading history.
Receive ABOS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Acumen Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ABOS Stock News Headlines

Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratings' latest research says 2026 could be very rough for some well-known stocks. A major shift now taking shape in the market could hit some of America's most-loved names hard. Weiss analysts have pinpointed five stocks they believe investors should steer clear of while it plays out.tc pixel
See More Headlines

ABOS Stock Analysis - Frequently Asked Questions

Acumen Pharmaceuticals' stock was trading at $2.11 at the beginning of 2026. Since then, ABOS shares have decreased by 90.7% and is now trading at $0.1960.

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) posted its quarterly earnings data on Monday, October, 26th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.39) by $0.04.
Read the conference call transcript
.

Acumen Pharmaceuticals (ABOS) raised $150 million in an IPO on Tuesday, June 29th 2021. The company issued 9,999,999 shares at $14.00-$16.00 per share.

Acumen Pharmaceuticals' top institutional investors include State Street Corp (1.16%) and Empowered Funds LLC (0.12%). Insiders that own company stock include Daniel Joseph Oconnell, Matt Zuga, Eric Siemers, Russell Barton, Derek M Meisner, James J Doherty, Nathan B Fountain and Derrell Porter.
View institutional ownership trends
.

Shares of ABOS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Acumen Pharmaceuticals investors own include Palantir Technologies (PLTR), Caribou Biosciences (CRBU), Cabaletta Bio (CABA), Cognition Therapeutics (CGTX), Advanced Micro Devices (AMD), Annexon (ANNX) and Ardelyx (ARDX).

Company Calendar

Last Earnings
10/26/2026
Today
11/18/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:ABOS
CIK
1576885
Fax
N/A
Employees
61
Year Founded
1996

Price Target and Rating

High Price Target
$1.00
Low Price Target
$1.00
Potential Upside/Downside
+410.2%
Consensus Rating
Reduce
Rating Score (0-4)
1.71
Research Coverage
7 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.54)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$121.33 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-166.49%
Return on Assets
-90.79%

Debt

Debt-to-Equity Ratio
0.17
Current Ratio
1.89
Quick Ratio
1.89

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.48 per share
Price / Book
0.41

Miscellaneous

Outstanding Shares
72,330,000
Free Float
64,950,000
Market Cap
$14.18 million
Optionable
Optionable
Beta
0.51

Social Links

7 Energy Stocks to Buy and Hold Forever Cover

Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.

Get This Free Report

This page (NASDAQ:ABOS) was last updated on 11/18/2026 by MarketBeat.com Staff.
From Our Partners